2022 American Transplant Congress
Kidney Transplant Recipients with Diabetic Mellitus Demand Larger Doses of Mycophenolate Mofetil
Kidney transplant surgery and Urology, Sapporo City General Hospital, Sapporo, Japan
*Purpose: To monitor blood concentration of immunosuppressants, therapeutic drug monitoring (TDM) is required at any point after kidney transplantation (KT) to prevent kidney graft from…2022 American Transplant Congress
The Role of Gut Microbiota in Tacrolimus Blood Level Fluctuation, Time in Therapeutic Range and AlloSure Donor Derived Cell-Free DNA, Controlling for CYP3A5
1George Mason University, Arlington, VA, 2George Washington University Hospital, Washington, DC
*Purpose: High tacrolimus variability (TV), low time in therapeutic range (TTR) and high percentage of donor derived cell-free DNA (dd-cfDNA) are associated with acute kidney…2022 American Transplant Congress
Impact of African American Race on Lcp-Tac Dosing and Clinical Outcomes
Medical University of South Carolina, Charleston, SC
*Purpose: The goal of this study was to assess the impact of African American (AA) race on the conversion ratio from Tac-IR to LCP-Tac, while…2022 American Transplant Congress
XR Tacrolimus Dosing By Ideal Body Weight Reduces Incidence Of Early Supratherapeutic Tacrolimus Concentrations
Pharmacy, NewYork-Presbyterian Hospital, New York, NY
*Purpose: At our center, the use of de novo Envarsus XR® (extended-release [XR] tacrolimus) dosed at 0.12 mg/kg is standard of care in adult kidney…2022 American Transplant Congress
The Role Of Gut Microbiome In Optimum Dose Selection Of Tacrolimus For Kidney Transplant Recipients
1George Mason University, Arlington, VA, 2George Washington University Hospital, Washington, DC
*Purpose: This study aims to validate and apply a personalized optimal dose selection model for Tacrolimus (Tac) for kidney transplant recipients at the George Washington…2021 American Transplant Congress
Letermovir Prophylaxis in Solid Organ Transplant – CMV Breakthrough and Tacrolimus Drug Interaction
*Purpose: Valganciclovir is the preferred drug for cytomegalovirus (CMV) prophylaxis in solid organ transplantation. A limitation to its use is profound myelosuppression. Letermovir is a…2021 American Transplant Congress
De-novo Use Comparison Between Extended-release Once-daily Tacrolimus (Envarsus Xr®) and Immediate-release Twice-daily Tacrolimus (Prograf®) – A Single Center’s Experience
*Purpose: Envarsus XR® is approved for de-novo use post-kidney transplantation at a higher starting dose (0.14mg/kg/day) as compared with Prograf® (0.1 mg/kg/day) despite better bioavailability.…2021 American Transplant Congress
Clinical Impact of Transplant Pharmacists on the Care of Solid Organ Transplant Recipients
1Temple University Hospital, Philadelphia, PA, 2Temple School of Pharmacy, Philadelphia, PA
*Purpose: The United Network for Organ Sharing (UNOS) and Centers for Medicare and Medicaid Services (CMS) requires transplant centers to document the participation of a…2021 American Transplant Congress
Valganciclovir Dosing for Cytomegalovirus Prophylaxis in Pediatric Solid Organ Transplant Recipients; Single Center Experience
*Purpose: The main objective of the study is to compare the efficacy of the different Valganciclovir dosing strategies in pediatric solid organ transplant recipients with…2021 American Transplant Congress
Evaluation of Low Dose Famciclovir as Herpes Simplex Virus and Varicella Zoster Virus Prophylaxis in Cytomegalovirus Low Risk Solid Organ Transplant Recipients
Massachusetts General Hospital, Boston, MA
*Purpose: Famciclovir is recommended for herpes simplex virus (HSV) and varicella-zoster virus (VZV) prophylaxis in cytomegalovirus (CMV) low risk (both donor and recipient CMV seronegative)…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 9
- Next Page »